The total return over the past 12 months is -47.61% vs. +19.88% for the S&P 500. So far it's up -40.37% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (47.61%) | +7.35% | +3.06% | +12.84% | +26.75% | +15.77% |
| Total Return CAGR | (47.61%) | +7.35% | +3.06% | +12.84% | +26.75% | +15.77% |
| Revenue CAGR | +95.14% | +57.15% | +47.53% | +66.18% | +30.33% | +33.57% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | +13.02% | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | +13.15% | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Alnylam Pharmaceuticals, Inc. (ALNY)
| Year | Start price | End price | ALNY Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $397.65 | $237.10 | (40.37%) | +13.42% | (53.79%) |
| 2025 | $235.31 | $397.65 | +68.99% | +17.72% | +51.27% |
| 2024 | $191.41 | $235.31 | +22.94% | +24.89% | (1.95%) |
| 2023 | $237.65 | $191.41 | (19.46%) | +26.19% | (45.65%) |
| 2022 | $169.58 | $237.65 | +40.14% | (18.17%) | +58.31% |
| 2021 | $129.97 | $169.58 | +30.48% | +28.74% | +1.74% |
| 2020 | $115.17 | $129.97 | +12.85% | +18.37% | (5.52%) |
| 2019 | $72.91 | $115.17 | +57.96% | +31.22% | +26.74% |
| 2018 | $127.05 | $72.91 | (42.61%) | (4.56%) | (38.05%) |
| 2017 | $37.44 | $127.05 | +239.34% | +21.70% | +217.64% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
